Mecolzine

Mesalazine, the active ingredient in Mecolzine, is a aminosalicylate presented as an oral formulation for oral use. It treats inflammatory bowel disease, including ulcerative colitis and Crohn's disease, in adult patients.

GNH USA supplies Mecolzine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mecolzine is an aminosalicylate used to manage inflammatory bowel disease and related conditions.

Ulcerative colitis: reduces mucosal inflammation and helps maintain remission. Crohn's disease: controls intestinal inflammation and alleviates symptoms. Maintenance therapy for IBD: supports long‑term disease control and reduces relapse risk.

Mecolzine may cause a range of adverse reactions.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Abdominal pain: cramping or discomfort. - Headache: occasional tension‑type headache. - Flatulence: increased intestinal gas. - Rash: mild skin irritation. - Taste alteration: temporary change in taste perception.

Serious or Rare Side Effects: - Severe allergic reaction: anaphylaxis or angioedema. - Pancreatitis: inflammation of the pancreas. - Blood disorders: leukopenia, anemia, or thrombocytopenia. - Liver enzyme elevation: signs of hepatic injury. - Interstitial nephritis: kidney inflammation. - Worsening colitis: severe flare of underlying disease.

Before initiating Mecolzine, certain safety considerations are recommended.

Renal function: assess baseline kidney status and monitor periodically. Hepatic function: evaluate liver enzymes prior to treatment. Blood counts: monitor for leukopenia or anemia during therapy. Pregnancy: use only if potential benefit justifies potential risk; data are limited. Drug interactions: review concomitant medicines for possible interactions. Store at ambient temperature: keep in the original container, protect from moisture and light.

Mecolzine can interact with several medications; awareness of interaction severity is important.

Major Interactions (Avoid): - Azathioprine: increased risk of bone‑marrow suppression. - Methotrexate: additive toxicity may occur. - Warfarin: potential enhancement of anticoagulant effect.

Moderate Interactions (Monitor Closely): - Antibiotics (e.g., ciprofloxacin): may affect mesalazine absorption. - NSAIDs: combined use can raise risk of renal impairment. - Oral contraceptives: possible reduction in contraceptive efficacy.